TY - JOUR
T1 - Somatic mosaicism in patients with Angelman syndrome and an imprinting defect
AU - Nazlican, Hülya
AU - Zeschnigk, Michael
AU - Claussen, Uwe
AU - Michel, Susanne
AU - Boehringer, Stefan
AU - Gillessen-Kaesbach, Gabriele
AU - Buiting, Karin
AU - Horsthemke, Bernhard
N1 - Funding Information:
We thank Drs K. Brockmann, J. Bürger, C. Camprubi, J. Clayton-Smith, V. Cohen, S. Demuth, A. Dobbie, D. Gläser, M. Hagen, R. Hennekam, J. Hurst, B. Janssen, P. Jonveaux, R. Koenig, B. Leheup, S. Mansour, R. McLeod, B. Mitulla, R. Newbury-Ecob, A. Petrick, H. Sawyer, S. Schuffenhauer, H. Seidel, A. Smith, M. Splitt, M. Suri, G. Tariverdian, U. Theile, L. Van Maldergem and P. Willems for sending DNA or blood samples and proven clinical and anthromometric data. We thank Danute Bergmann for technical assistance. Part of the work was supported by the Deutsche Forschungsgemeinschaft (BU907/1-2).
PY - 2004/11/1
Y1 - 2004/11/1
N2 - Angelman syndrome is a neurogenetic disorder caused by the loss of function of the imprinted UBE3A gene in 15q11-q13. In a small group of patients, the disease is due to an imprinting defect (ID) that silences the maternal UBE3A allele. The presence of a faint maternal band detected by methylation-specific PCR analysis of the SNURF-SNRPN locus in approximately one-third of patients who have an ID but no imprinting center deletion suggested that these patients are mosaics of ID cells and normal cells. In two patients studied, somatic mosaicism was proven by molecular and cellular cloning, respectively. X inactivation studies of cloned fibroblasts from one patient suggest that ID occurred before the blastocyst stage. To quantify the degree of mosaicism, we developed a novel quantitative methylation assay based on real-time PCR. In 24 patients tested, the percentage of normal cells ranged from <1% to 40%. Regression analyst suggests that patients with a higher percentage of normally methylated cells tend to have milder clinical symptoms than patients with a lower percentage. In conclusion, we suggest that the role of mosaic imprinting defects in mental retardation is underestimated.
AB - Angelman syndrome is a neurogenetic disorder caused by the loss of function of the imprinted UBE3A gene in 15q11-q13. In a small group of patients, the disease is due to an imprinting defect (ID) that silences the maternal UBE3A allele. The presence of a faint maternal band detected by methylation-specific PCR analysis of the SNURF-SNRPN locus in approximately one-third of patients who have an ID but no imprinting center deletion suggested that these patients are mosaics of ID cells and normal cells. In two patients studied, somatic mosaicism was proven by molecular and cellular cloning, respectively. X inactivation studies of cloned fibroblasts from one patient suggest that ID occurred before the blastocyst stage. To quantify the degree of mosaicism, we developed a novel quantitative methylation assay based on real-time PCR. In 24 patients tested, the percentage of normal cells ranged from <1% to 40%. Regression analyst suggests that patients with a higher percentage of normally methylated cells tend to have milder clinical symptoms than patients with a lower percentage. In conclusion, we suggest that the role of mosaic imprinting defects in mental retardation is underestimated.
UR - http://www.scopus.com/inward/record.url?scp=8444240032&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddh296
DO - 10.1093/hmg/ddh296
M3 - Journal articles
C2 - 15385437
AN - SCOPUS:8444240032
SN - 0964-6906
VL - 13
SP - 2547
EP - 2555
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 21
ER -